SCHEMBL4110871

SCHEMBL4110871

Cc1ccncc1-c1nc2ccccc2[nH]1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.69
NPC1 O15118 10/20 0.69
RAB9A P51151 10/20 0.69
SMN1; SMN2 Q16637 6/20 0.69
HPGD P15428 6/20 0.69
NPSR1 Q6W5P4 4/20 0.69
HTT P42858 1/20 0.69
KDM4E B2RXH2 10/20 0.57
PKN1 Q16512 1/20 0.57
PKN2 Q16513 1/20 0.57
LDHA P00338 1/20 0.56
EPHX2 P34913 1/20 0.56
METAP2 P50579 1/20 0.55
HSD17B10 Q99714 5/20 0.55
PKM P14618 4/20 0.55
TP53 P04637 2/20 0.55
ABCB11 O95342 1/20 0.55
PDE5A O76074 2/20 0.52
GAA P10253 2/20 0.51
MAPT P10636 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4118075 0.88 ALDH1A1 (0.69) ALDH1A1NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL29411978 0.82 NPC1 (1.00) ALDH1A1NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL3170855 0.82 NPC1 (1.00) ALDH1A1NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL31458736 0.81 F7 (0.60) ALDH1A1NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL9986747 0.81 KDM4E (0.69) ALDH1A1NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL221334 0.81 ALDH1A1 (0.69) ALDH1A1NPC1RAB9ASMN1; SMN2HPGD
Hydrochloric Acid SCHEMBL7279355 0.80 ALDH1A1 (0.67) ALDH1A1NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL18438604 0.78 CLK2 (0.60) ALDH1A1NPC1RAB9ASMN1; SMN2HPGD
SCHEMBL15862395 0.78 WNT1 (0.74) CDK2
SCHEMBL4110856 0.78 ALDH1A1 (0.69) ALDH1A1NPC1RAB9ASMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007117778-A9 QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS KALYPSYS INC (US) 2009-05-22 WO disclosed
EP-1986747-A2 QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS Kalypsys, Inc. (US) 2008-11-05 EP disclosed
US-20080139558-A1 QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS KALYPSYS, INC. (US) 2008-06-12 US disclosed
WO-2007117778-A2 QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS KALYPSYS, INC. (US) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139558-A1 QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS NOS2, NOS1, NQO2 ALDH1A1 1044/4885NPC1 1303/4885RAB9A 1758/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.